TriSalus Life Sciences^® (Nasdaq: TLSI) is an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. Its platform includes two FDA-cleared devices and a clinical-stage immunotherapeutic candidate.